Latest Breaking News On - Advanced colorectal cancer - Page 2 : comparemela.com

AMGEN PRESENTS NEW LUMAKRAS® (SOTORASIB) CODEBREAK 200 CNS DATA AT ASCO 2023

/PRNewswire/ Amgen (NASDAQ:AMGN) today announced the presentation of new data from the CodeBreaK clinical trial program, the most comprehensive global.

United arab emiratesUnited statesSouth koreaHong kongSaudi arabiaPuerto ricoMacau generalUnited kingdomGreat britainCelllung cancerandJessica akopyanDavids hongStevens johnsonMichael strapazonMelissal johnsonSpira al

Trifluridine–Tipiracil and Bevacizumab Improves Survival in Metastatic Pretreated Colorectal Cancer

1. The median overall survival was 10.8 months in the combination group (FTD–TPI + bevacizumab) and 7.5 months in the FTD–TPI alone group, with HR 0.61. 2. The most common adverse events in both groups included neutropenia, nausea, and anemia. Evidence Rating Level: 1 (Excellent) Study Rundown: Trifluridine-tipiracil (cytotoxic nucleic acid analogue) is commonly used

Rating levelAdvanced colorectal cancerTas 102Trifluridine tipiracilChronic disease

Wugen Presents Data on WU-NK-101 in Combination with Cetuximab in Preclinical Models of Advanced Colorectal Cancer (CRC) at ASCO Gastrointestinal Cancers Symposium

Wugen Presents Data on WU-NK-101 in Combination with Cetuximab in Preclinical Models of Advanced Colorectal Cancer (CRC) at ASCO Gastrointestinal Cancers Symposium
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesWest hallSan franciscoJohn muthJan davidson moncadaElsie yauStern investor relations incAmerican society of clinical oncologyWugen incWall streetAmerican societyClinical oncologyGastrointestinal cancers symposiumChief medical officerCancers symposiumEnhanced memory natural killer

LUMAKRAS® (SOTORASIB) COMBINED WITH VECTIBIX® (PANITUMUMAB) SHOWS CONFIRMED 30% OBJECTIVE RESPONSE RATE IN PATIENTS WITH KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER

/PRNewswire/ Amgen (NASDAQ: AMGN) today announced updated data from its Phase 1b CodeBreaK 101 study, one of the most comprehensive global clinical.

Hong kongFrance generalUnited kingdomUnited arab emiratesPuerto ricoSaudi arabiaSouth koreaMacau generalGreat britainMegan foxJessica akopyanStevens johnsonYasutoshi kubokiVan cutsemDavidm reeseNational cancer center hospital

LUMAKRAS™ (Sotorasib) Combined With Vectibix® (Panitumumab) Showed Encouraging Efficacy And Safety In Patients With KRAS G12C-Mutated Colorectal Cancer

/PRNewswire/ Amgen (NASDAQ: AMGN) today announced the first combination study results from the Phase 1b/2 CodeBreaK 101 study, the most comprehensive global.

United arab emiratesHong kongUnited kingdomPuerto ricoSouth koreaGreat britainMegan foxTrish rowlandStevens johnsonMarwang fakihVan cutsemDavidm reeseKyowa kirin co ltdEuropean society of medical oncologyWorld health organizationDrug administration